Position of the Transparency Council – Emcitate (tiratricol)
At its meeting on 23 December 2024, the Transparency Council adopted position No. 154/2024 on the appropriateness of issuing reimbursement approvals for the drug Emcitate (tiratricol) for the indication Allan-Herndon-Dudley syndrome